RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights.
暂无分享,去创建一个
F. McCormick | V. Staedtke | J. Blakeley | R. Cagan | K. Sarin | Steven D. Rhodes | Matthew R. Steensma | Annette C. Bakker | C. Romo | Ina Ly | Sang Y. Lee
[1] K. Sarin,et al. Neurofibromatosis Type 1 and Risk of Skin Cancer. , 2022, JAMA dermatology.
[2] R. Betensky,et al. Genomic and transcriptomic analyses of NF1-mutant melanoma identify potential targeted approach for treatment. , 2022, The Journal of investigative dermatology.
[3] Matthew R. Schwartz,et al. Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study , 2022, Pigment cell & melanoma research.
[4] L. Le,et al. Neurofibromin and suppression of tumorigenesis: beyond the GAP , 2022, Oncogene.
[5] J. Whisstock,et al. The cryo-EM structure of the human neurofibromin dimer reveals the molecular basis for neurofibromatosis type 1 , 2021, Nature Structural & Molecular Biology.
[6] B. Rupp,et al. The structure of neurofibromin isoform 2 reveals different functional states , 2021, Nature.
[7] W. Wang,et al. Combined CDK inhibition overcomes MEK inhibitor resistance in plexiform neurofibroma of neurofibromatosis type I. , 2021, The Journal of investigative dermatology.
[8] L. Klesse,et al. Insights into the Pathogenesis of NF1-Associated Neoplasms , 2021, JID innovations.
[9] J. Brosseau,et al. Human cutaneous neurofibroma matrisome revealed by single-cell RNA sequencing , 2021, Acta neuropathologica communications.
[10] F. McCormick,et al. SPRED proteins and their roles in signal transduction, development, and malignancy , 2020, Genes & development.
[11] D. Gutmann,et al. Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins. , 2020, The Journal of clinical investigation.
[12] S. Naber,et al. Decellularized extracellular matrix scaffolds identify full-length collagen VI as a driver of breast cancer cell invasion in obesity and metastasis , 2020, Science Advances.
[13] S. Steinberg,et al. Selumetinib in Children with Inoperable Plexiform Neurofibromas. , 2020, The New England journal of medicine.
[14] R. Tiu,et al. Clinical Characteristics, Treatments, and Concurrent Mutations in Non-Small Cell Lung Cancer Patients With NF1 Mutations. , 2020, Clinical lung cancer.
[15] D. Esposito,et al. Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR , 2020, Cell reports.
[16] S. Steinberg,et al. Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: Growth analysis of plexiform neurofibromas and distinct nodular lesions. , 2020, Neuro-oncology.
[17] Christopher B. Stanley,et al. Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer , 2019, The Journal of Biological Chemistry.
[18] Douglas C. Miller,et al. Assessing interobserver variability and accuracy in the histological diagnosis and classification of cutaneous neurofibromass , 2019, Neuro-oncology advances.
[19] C. Pratilas,et al. Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling , 2019, bioRxiv.
[20] I. Blanco,et al. Cutaneous neurofibromas: patients’ medical burden, current management and therapeutic expectations: results from an online European patient community survey , 2019, Orphanet Journal of Rare Diseases.
[21] G. Sandusky,et al. Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of Nf1-Deficient Mice , 2019, Molecular Cancer Therapeutics.
[22] Pushpankur Ghoshal,et al. Loss of GTPase activating protein neurofibromin stimulates paracrine cell communication via macropinocytosis , 2019, Redox biology.
[23] G. Sandusky,et al. Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation. , 2019, Human molecular genetics.
[24] Nancy F. Hansen,et al. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define pre-malignant neurofibromatosis type 1-associated atypical neurofibromas. , 2019, Neuro-oncology.
[25] J. Brosseau,et al. NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation , 2018, Nature Communications.
[26] Robert J. Allaway,et al. Spatiotemporal Loss of NF1 in Schwann Cell Lineage Leads to Different Types of Cutaneous Neurofibroma Susceptible to Modification by the Hippo Pathway. , 2018, Cancer discovery.
[27] P. Wolkenstein,et al. Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with Nf1 Knockout in Boundary Cap Cells. , 2018, Cancer discovery.
[28] A. Stemmer-Rachamimov,et al. Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings , 2018, Human mutation.
[29] Douglas C. Miller,et al. Cutaneous neurofibromas , 2018, Neurology.
[30] J. Brosseau,et al. Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis , 2018, The Journal of clinical investigation.
[31] B. Korf,et al. Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study , 2018, Orphanet Journal of Rare Diseases.
[32] K. Kosaki,et al. Natural course and characteristics of cutaneous neurofibromas in neurofibromatosis 1 , 2018, The Journal of dermatology.
[33] E. Zackai,et al. Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844–848 , 2017, American journal of human genetics.
[34] J. Teer,et al. The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation , 2017, Scientific Reports.
[35] Alexander V. Favorov,et al. Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy , 2017, Clinical Cancer Research.
[36] N. Ratner,et al. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. , 2016, The New England journal of medicine.
[37] S. Peltonen,et al. Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] N. Kirkpatrick,et al. The use of electrodessication in the treatment of cutaneous neurofibromatosis: A retrospective patient satisfaction outcome assessment. , 2016, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.
[39] D. Larouche,et al. 27.12 MHz Radiofrequency Ablation for Benign Cutaneous Lesions , 2016, BioMed research international.
[40] R. Mali,et al. Nf1+/- monocytes/macrophages induce neointima formation via CCR2 activation. , 2016, Human molecular genetics.
[41] A. Halpern,et al. NF1 Mutations Are Common in Desmoplastic Melanoma , 2015, The American journal of surgical pathology.
[42] V. Riccardi. Ketotifen suppression of NF1 neurofibroma growth over 30 years , 2015, American journal of medical genetics. Part A.
[43] Alcino J. Silva,et al. HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1 , 2015, Molecular Psychiatry.
[44] N. Ratner,et al. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor , 2015, Nature Reviews Cancer.
[45] P. Wolkenstein,et al. Treatment of Neurofibromas with a Carbon Dioxide Laser: A Retrospective Cross-Sectional Study of 106 Patients , 2015, Dermatology.
[46] C. Liao,et al. Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibroma. , 2014, Cancer cell.
[47] L. Qin,et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors , 2014, Nature Genetics.
[48] A. Guha,et al. Neurofibromin interacts with the cytoplasmic Dynein Heavy Chain 1 in melanosomes of human melanocytes , 2013, FEBS letters.
[49] G. Hutchins,et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. , 2012, The Lancet. Oncology.
[50] N. Ratner,et al. In vivo regulation of TGF-β by R-Ras2 revealed through loss of the RasGAP protein NF1. , 2012, Cancer research.
[51] L. Kluwe,et al. Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1 , 2012, Orphanet Journal of Rare Diseases.
[52] A. Burlingame,et al. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. , 2012, Genes & development.
[53] D. Gutmann,et al. Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner , 2012, Molecular and Cellular Neuroscience.
[54] T. de Ravel,et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors , 2011, Genes, chromosomes & cancer.
[55] G. H. Vries,et al. Aberrant cAMP Metabolism in NF1 Malignant Peripheral Nerve Sheath Tumor Cells , 2011, Neurochemical Research.
[56] Jan Koster,et al. NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome , 2010, Cell.
[57] N. Warrington,et al. Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. , 2010, Cancer research.
[58] Feng-Chun Yang,et al. Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells , 2010, Current opinion in hematology.
[59] Frank McCormick,et al. The molecular pathology of cancer , 2010, Nature Reviews Clinical Oncology.
[60] V. Golubovskaya,et al. Neurofibromin physically interacts with the N‐terminal domain of focal adhesion kinase , 2009, Molecular carcinogenesis.
[61] Kathleen R. Cho,et al. Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. , 2008, Neoplasia.
[62] J. Chernoff,et al. Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells. , 2008, Blood.
[63] G. Hutchins,et al. Nf1-Dependent Tumors Require a Microenvironment Containing Nf1 +/−- and c-kit-Dependent Bone Marrow , 2008, Cell.
[64] Alcino J. Silva,et al. Neurofibromin Regulation of ERK Signaling Modulates GABA Release and Learning , 2008, Cell.
[65] H. Weinberg,et al. Electrosurgical excision technique for the treatment of multiple cutaneous lesions in neurofibromatosis type I. , 2008, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.
[66] A. Stemmer-Rachamimov,et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. , 2008, Cancer cell.
[67] L. Parada,et al. Tumor microenvironment and neurofibromatosis type I: connecting the GAPs , 2007, Oncogene.
[68] M. Wilm,et al. The sec14 homology module of neurofibromin binds cellular glycerophospholipids: mass spectrometry and structure of a lipid complex. , 2007, Journal of molecular biology.
[69] D. Ingram,et al. K-ras Is Critical for Modulating Multiple c-kit-Mediated Cellular Functions in Wild-Type and Nf1+/− Mast Cells1 , 2007, The Journal of Immunology.
[70] F. Speleman,et al. Somatic loss of wild type NF1 allele in neurofibromas: Comparison of NF1 microdeletion and non‐microdeletion patients , 2006, Genes, chromosomes & cancer.
[71] G. Page,et al. Impact of neurofibromatosis 1 on Quality of Life: A cross‐sectional study of 176 American cases , 2006, American journal of medical genetics. Part A.
[72] L. Parada,et al. Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. , 2006, Human molecular genetics.
[73] I. D'Angelo,et al. A novel bipartite phospholipid‐binding module in the neurofibromatosis type 1 protein , 2006, EMBO reports.
[74] F. Mertens,et al. Biallelic somatic inactivation of the NF1 gene through chromosomal translocations in a sporadic neurofibroma , 2005, International journal of cancer.
[75] D. Gutmann,et al. Neurofibromin Regulates Neural Stem Cell Proliferation, Survival, and Astroglial Differentiation In Vitro and In Vivo , 2005, The Journal of Neuroscience.
[76] D. Gutmann,et al. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. , 2005, Cancer research.
[77] D. Gutmann,et al. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. , 2003, Cancer research.
[78] C. James,et al. Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1 , 2003, Neurology.
[79] D. Gutmann,et al. The Neurofibromatosis 1 Gene Product Neurofibromin Regulates Pituitary Adenylate Cyclase-Activating Polypeptide-Mediated Signaling in Astrocytes , 2003, The Journal of Neuroscience.
[80] X. Estivill,et al. Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients , 2003, Journal of medical genetics.
[81] Y. Harada,et al. Novel Mutations of Neurofibromatosis Type 1 Gene in Small Cell Lung Cancers , 2003, Surgery Today.
[82] D. Burns,et al. Neurofibromas in NF1: Schwann Cell Origin and Role of Tumor Environment , 2002, Science.
[83] D. Evans,et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1 , 2002, Journal of medical genetics.
[84] Alcino J. Silva,et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1 , 2002, Nature.
[85] Yu Cheng,et al. Differential localization of the neurofibromatosis 1 (NF1) gene product, neurofibromin, with the F-actin or microtubule cytoskeleton during differentiation of telencephalic neurons. , 2001, Brain research. Developmental brain research.
[86] M. Tatagiba,et al. Loss of NF1 Alleles Distinguish Sporadic from NF1‐Associated Pilocytic Astrocytomas , 2001, Journal of neuropathology and experimental neurology.
[87] David A. Williams,et al. Hyperactivation of P21ras and the Hematopoietic-Specific Rho Gtpase, Rac2, Cooperate to Alter the Proliferation of Neurofibromin-Deficient Mast Cells in Vivo and in Vitro , 2001, The Journal of experimental medicine.
[88] R. Gutzmer,et al. Allelic loss at the neurofibromatosis type 1 (NF1) gene locus is frequent in desmoplastic neurotropic melanoma , 2000, Human Genetics.
[89] David A. Williams,et al. Genetic and Biochemical Evidence That Haploinsufficiency of the Nf1 Tumor Suppressor Gene Modulates Melanocyte and Mast Cell Fates in Vivo , 2000, The Journal of experimental medicine.
[90] K. Shannon,et al. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. , 1999, American journal of medical genetics.
[91] R. Berkowitz,et al. Differential expression of NF1 type I and type II isoforms in sporadic borderline and invasive epithelial ovarian tumors , 1999, Oncogene.
[92] K. Shannon,et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. , 1998, Blood.
[93] X. Estivill,et al. Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. , 1997, American journal of human genetics.
[94] D. Cooper,et al. Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene , 1996, Human Genetics.
[95] D. Viskochil,et al. Identification of NF1 mutations in both alleles of a dermal neurofibroma , 1996, Nature Genetics.
[96] P S Harper,et al. Molecular genetics of neurofibromatosis type 1 (NF1). , 1996, Journal of medical genetics.
[97] S. Colman,et al. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene , 1995, Nature Genetics.
[98] D. Gutmann,et al. Loss of neurofibromatosis type I (NFI) gene expression in pheochromocytomas from patients without NFI , 1994, Genes, chromosomes & cancer.
[99] C. Der,et al. The Ras signal transduction pathway , 1994, Cancer and Metastasis Reviews.
[100] A. Look,et al. Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[101] M. Daston,et al. Neurofibromin, a predominantly neuronal GTPase activating protein in the adult, is ubiquitously expressed during development , 1992, Developmental dynamics : an official publication of the American Association of Anatomists.
[102] B. Brownstein,et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. , 1990, Science.
[103] P. O'Connell,et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus , 1990, Cell.
[104] S. Huson,et al. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling. , 1989, Journal of medical genetics.
[105] J. L. Bos,et al. ras oncogenes in human cancer: a review. , 1989, Cancer research.
[106] P. Rowley,et al. Molecular genetic analysis of tumors in von recklinghausen neurofibromatosis: Loss of heterozygosity for chromosome 17 , 1989, Genes, chromosomes & cancer.
[107] H. Larjava,et al. Collagens in Neurofibromas and Neurofibroma Cell Cultures , 1986, Annals of the New York Academy of Sciences.
[108] M. Skolnick,et al. The Genetic Aspects of Neurofibromatosis a , 1986, Annals of the New York Academy of Sciences.
[109] A. Leplège,et al. Visibility of neurofibromatosis 1 and psychiatric morbidity. , 2003, Archives of dermatology.
[110] M. Barbacid. ras genes. , 1987, Annual review of biochemistry.